New combo therapy shows promise for relapsed leukemia
NCT ID NCT03160079
First seen Nov 10, 2025 · Last updated May 02, 2026 · Updated 23 times
Summary
This early-phase study tested a combination of two drugs, blinatumomab and pembrolizumab, in 16 adults with a type of blood cancer (B-cell acute lymphoblastic leukemia) that had come back or not responded to prior treatment. The goal was to see if adding pembrolizumab to blinatumomab could improve the number of patients who achieve complete remission (no detectable cancer cells). Participants had high levels of cancer cells in their bone marrow at the start.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC Irvine Health Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UCSF Comprehensive Cancer Center
San Francisco, California, 94143, United States
-
UCSF Fresno Community Cancer Institute
Clovis, California, 93611, United States
Conditions
Explore the condition pages connected to this study.